您的购物车当前为空
别名 JNJ26076713
JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.

JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 37,400 | 8-10周 |
JNJ-26076713 相关产品
| 产品描述 | JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy. |
| 靶点活性 | αvβ3 integrin:2.3 nM, αvβ5 integrin:6.3 nM |
| 别名 | JNJ26076713 |
| 分子量 | 490.64 |
| 分子式 | C29H38N4O3 |
| CAS No. | 669076-03-3 |
| 密度 | 1.31 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容